$2.57T
Total marketcap
$176.23B
Total volume
BTC 49.95%     ETH 15.88%
Dominance

BeiGene BGNE Stock

168.5 USD {{ price }} -0.882353% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
18.59B USD
LOW - HIGH [24H]
168.33 - 170.77 USD
VOLUME [24H]
154.83K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-8.46 USD

BeiGene Price Chart

BeiGene BGNE Financial and Trading Overview

BeiGene stock price 168.5 USD
Previous Close 208.12 USD
Open 193.51 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 191.15 - 208.5 USD
52 Week Range 124.46 - 280.62 USD
Volume 474.57K USD
Avg. Volume 193.3K USD
Market Cap 21.05B USD
Beta (5Y Monthly) 0.786619
PE Ratio (TTM) N/A
EPS (TTM) -8.46 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 316.74 USD

BGNE Valuation Measures

Enterprise Value 17.62B USD
Trailing P/E N/A
Forward P/E -21.781149
PEG Ratio (5 yr expected) 0.11
Price/Sales (ttm) 13.519978
Price/Book (mrq) 5.037334
Enterprise Value/Revenue 11.315
Enterprise Value/EBITDA -10.686

Trading Information

BeiGene Stock Price History

Beta (5Y Monthly) 0.786619
52-Week Change 52.14%
S&P500 52-Week Change 20.43%
52 Week High 280.62 USD
52 Week Low 124.46 USD
50-Day Moving Average 240.2 USD
200-Day Moving Average 212.18 USD

BGNE Share Statistics

Avg. Volume (3 month) 193.3K USD
Avg. Daily Volume (10-Days) 240.63K USD
Shares Outstanding 104.72M
Float 57.08M
Short Ratio 10.63
% Held by Insiders 19.84%
% Held by Institutions 52.48%
Shares Short 1.84M
Short % of Float N/A
Short % of Shares Outstanding 1.76%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -123.11%
Operating Margin (ttm) -110.36%
Gross Margin -26.017%
EBITDA Margin -105.88%

Management Effectiveness

Return on Assets (ttm) -15.36%
Return on Equity (ttm) -38.17%

Income Statement

Revenue (ttm) 1.56B USD
Revenue Per Share (ttm) 15.04 USD
Quarterly Revenue Growth (yoy) 46.00%
Gross Profit (ttm) -511062000 USD
EBITDA -1648758016 USD
Net Income Avi to Common (ttm) -1917048064 USD
Diluted EPS (ttm) -17.41
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 3.87B USD
Total Cash Per Share (mrq) 37.13 USD
Total Debt (mrq) 545.19M USD
Total Debt/Equity (mrq) 13.11 USD
Current Ratio (mrq) 3.75
Book Value Per Share (mrq) 39.91

Cash Flow Statement

Operating Cash Flow (ttm) -1823832960 USD
Levered Free Cash Flow (ttm) -1309241344 USD

Profile of BeiGene

Country United States
State N/A
City Grand Cayman
Address 94 Solaris Avenue
ZIP KY1-1108
Phone 345-949 4123
Website https://www.beigene.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 9400

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Q&A For BeiGene Stock

What is a current BGNE stock price?

BeiGene BGNE stock price today per share is 168.5 USD.

How to purchase BeiGene stock?

You can buy BGNE shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BeiGene?

The stock symbol or ticker of BeiGene is BGNE.

Which industry does the BeiGene company belong to?

The BeiGene industry is Biotechnology.

How many shares does BeiGene have in circulation?

The max supply of BeiGene shares is 110.33M.

What is BeiGene Price to Earnings Ratio (PE Ratio)?

BeiGene PE Ratio is now.

What was BeiGene earnings per share over the trailing 12 months (TTM)?

BeiGene EPS is -8.46 USD over the trailing 12 months.

Which sector does the BeiGene company belong to?

The BeiGene sector is Healthcare.

BeiGene BGNE included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD